Featured Research

from universities, journals, and other organizations

Withdrawal Drug Offers Symptom Relief To Crohn's Sufferers, Study Shows

Date:
February 4, 2007
Source:
Penn State
Summary:
A Penn State College of Medicine pilot study suggests a low dose of naltrexone, a drug used to ease symptoms of alcohol and drug addiction, may also bring relief to people with Crohn's disease, a chronic inflammatory disorder of the intestine that affects an estimated 500,000 Americans. The study results were released online this week in an early edition of the American Journal of Gastroenterology.

A Penn State College of Medicine pilot study suggests a low dose of naltrexone, a drug used to ease symptoms of alcohol and drug addiction, may also bring relief to people with Crohn's disease, a chronic inflammatory disorder of the intestine that affects an estimated 500,000 Americans. The study results were released online this week in an early edition of the American Journal of Gastroenterology.

A team of researchers led by gastroenterologist Jill P. Smith, M.D., and Ian S. Zagon, Ph.D., Distinguished Professor of neural and behavioral sciences, at the College of Medicine and Penn State Milton S. Hershey Medical Center, received NIH funding last summer to initiate a phase 2 trial of low-dose naltrexone and Crohn's.

In the pilot study, patients with diagnosed Crohn's disease were treated with a low dose of naltrexone and monitored for improvement of symptoms for 12 weeks. Quality of life surveys were given every four weeks for 16 weeks. The results, published this week, show that 89 percent of participants showed an improvement with therapy, while 67 percent achieved remission of symptoms. The only side effect to treatment was sleep disturbance in some patients.

Typical treatment for Crohn's involves using steroids or corticosteroids, which suppress the immune system and can have other toxic side effects. Treatment is often time-intensive and expensive, as well.

"This is a novel approach to treating a common disease, and it's simple, it's safe, and it costs far less than current standards of treatment," Smith said. "We don't yet know the exact mechanisms involved in how it works, but we're working on that, as well."

In a related study, Smith and other College of Medicine researchers are studying the chemical and molecular mechanisms involved in suppression of inflammatory responses in the intestine when animals are treated with naltrexone.

Team members on the first study include Heather Stock, M.S.I.V., Sandra Bingaman, R.N. and David Mauger, Ph.D., Department of Health Evaluation Sciences, Penn State College of Medicine.

Members of the second study team include Gail L. Matters, Ph.D., and John F. Harms, Ph.D., Department of Biochemistry and Molecular Biology; Leo Fitzpatrick, Ph.D., Department of Surgery; and Anuj Parikh, B.S., and Nicholas Nilo, Department of Medicine, Penn State College of Medicine.

The phase 2 study of naltrexone for Crohn's is also supported by funding by the Broad Medical Research Program.


Story Source:

The above story is based on materials provided by Penn State. Note: Materials may be edited for content and length.


Cite This Page:

Penn State. "Withdrawal Drug Offers Symptom Relief To Crohn's Sufferers, Study Shows." ScienceDaily. ScienceDaily, 4 February 2007. <www.sciencedaily.com/releases/2007/02/070203103350.htm>.
Penn State. (2007, February 4). Withdrawal Drug Offers Symptom Relief To Crohn's Sufferers, Study Shows. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2007/02/070203103350.htm
Penn State. "Withdrawal Drug Offers Symptom Relief To Crohn's Sufferers, Study Shows." ScienceDaily. www.sciencedaily.com/releases/2007/02/070203103350.htm (accessed July 25, 2014).

Share This




More Health & Medicine News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Doctor At Forefront Of Fighting Ebola Outbreak Gets Ebola

Newsy (July 24, 2014) Sheik Umar Khan has treated many of the people infected in the Ebola outbreak, and now he's become one of them. Video provided by Newsy
Powered by NewsLook.com
Condemned Man's US Execution Takes Nearly Two Hours

Condemned Man's US Execution Takes Nearly Two Hours

AFP (July 24, 2014) America's death penalty debate raged Thursday after it took nearly two hours for Arizona to execute a prisoner who lost a Supreme Court battle challenging the experimental lethal drug cocktail. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins